Experience

• • Roche, a multinational healthcare company, in its exclusive collaboration and licensing agreement with Zealand Pharma, a biotechnology company focused on the discovery and development of innovative peptide-based medicines.
  • Ratio Therapeutics, a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, on its exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
  • Lexicon Pharmaceuticals in its exclusive license agreement with Novo Nordisk for an oral non-incretin development candidate in obesity and associated metabolic disorders.
  • An antibody services and technology provider in library development agreements with various partners, including AstraZeneca, Scholar Rock and Biogen.
  • Verve Therapeutics in a strategic collaboration with Vertex Pharmaceuticals, a global biotechnology company.
  • ImaginAb in its divestiture of its radiopharmaceutical therapy business to Telix Pharmaceuticals.
  • Benu Networks, a leading software and solutions provider, in its acquisition by Ciena Corporation.
  • Eliem Therapeutics in its acquisition of Tenet Medicines, a development-stage private biotechnology company.
  • Iveric Bio in the acquisition by Opus Genetics of Iveric Bio’s emerging gene therapies for inherited retinal diseases.
  • Zaius, a customer data platform (CDP), in its acquisition by Optimizely (formerly Episerver), a leading provider of digital experience platform solutions.
  • Amplitude Healthcare Acquisition Corporation in its business combination with Jasper Therapeutics.